Compare Bank of New York Mellon Corp (BNY) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of New York Mellon Corp vs Neurocrine Biosciences Inc — how do they compare? Bank of New York Mellon Corp trades at $153.3 (market cap $106.05B), while Neurocrine Biosciences Inc trades at $172.04 (market cap $17.30B). The key difference: Bank of New York Mellon Corp is far larger — about 6.1× Neurocrine Biosciences Inc's market cap, and Bank of New York Mellon Corp pays a 1.37% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| BNY | NBIX | |
|---|---|---|
Market Cap | $106.05B | $17.30B |
Sector | Financials | Health |
52-Week High | $154.50 | $180.55 |
52-Week Low | $95.16 | $123.10 |
Dividend Yield | 1.37% | — |
Enterprise Value | — | $16.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Neurocrine Biosciences (NBIX) trades at $174.10, down 1.7% on the day but maintains strong technical momentum with bullish moving averages and support at $173. The company demonstrates robust fundamentals with Q1 2026 revenue growth of 44% year-over-year to $811 million and consistent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected. Recent pipeline advancements include Phase 2 studies for crinecerfont and positive VYKAT XR data presented at ENDO 2026.
NBIX presents compelling growth prospects with analyst consensus price target of $195.75 (12% upside) and 86% buy ratings. Key opportunities include blockbuster drug performance and strategic acquisitions, while risks involve clinical trial outcomes and competitive pressures in neuroscience therapeutics. The stock's current valuation at 26.5x P/E reflects growth expectations but requires continued execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of New York Mellon Corp
BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.
Read more on BNY →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
